Cooper Companies (NASDAQ:COO) Updates FY 2026 Earnings Guidance

Cooper Companies (NASDAQ:COO) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 4.510-4.550 for the period, compared to the consensus estimate of 4.630. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.3 billion. Cooper Companies also updated its Q4 2026 guidance to 1.050-1.090 EPS.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on COO shares. Robert W. Baird reduced their price objective on Cooper Companies from $98.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Mizuho set a $85.00 price target on Cooper Companies and gave the company an “outperform” rating in a research note on Thursday, June 4th. Citigroup restated a “neutral” rating and set a $80.00 price target (up from $76.00) on shares of Cooper Companies in a report on Thursday, August 13th. Wells Fargo & Company reaffirmed a “sell” rating and issued a $66.00 price objective (down from $82.00) on shares of Cooper Companies in a research note on Friday, June 5th. Finally, The Goldman Sachs Group set a $61.00 price objective on shares of Cooper Companies in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Cooper Companies has an average rating of “Hold” and an average target price of $81.64.

Cooper Companies Trading Down 6.2%

Shares of COO traded down $4.21 during trading hours on Wednesday, hitting $63.48. 8,920,917 shares of the stock were exchanged, compared to its average volume of 2,349,299. Cooper Companies has a fifty-two week low of $58.89 and a fifty-two week high of $89.83. The business has a 50-day moving average of $72.59 and a 200-day moving average of $70.17. The firm has a market capitalization of $12.38 billion, a P/E ratio of 53.80, a price-to-earnings-growth ratio of 1.82 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, research analysts expect that Cooper Companies will post 4.63 EPS for the current year.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Hedge Funds Weigh In On Cooper Companies

Institutional investors have recently added to or reduced their stakes in the business. C M Bidwell & Associates Ltd. acquired a new stake in shares of Cooper Companies during the 4th quarter worth approximately $115,000. Brown Brothers Harriman & Co. lifted its position in shares of Cooper Companies by 88.4% during the 4th quarter. Brown Brothers Harriman & Co. now owns 1,984 shares of the medical device company’s stock valued at $163,000 after acquiring an additional 931 shares during the period. J.Safra Asset Management Corp lifted its position in shares of Cooper Companies by 82.2% during the 4th quarter. J.Safra Asset Management Corp now owns 1,031 shares of the medical device company’s stock valued at $85,000 after acquiring an additional 465 shares during the period. Parallel Advisors LLC boosted its stake in Cooper Companies by 72.8% during the fourth quarter. Parallel Advisors LLC now owns 1,583 shares of the medical device company’s stock worth $130,000 after acquiring an additional 667 shares in the last quarter. Finally, Advisory Services Network LLC bought a new position in Cooper Companies during the third quarter worth $163,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.